What did FDA actually say in the Gram Peptides warning letter, and why does it matter for my storefront?

SHORT ANSWER

FDA reviewed grampeptides.com from January to March 2026, quoted product-page language about appetite, glucose, and body weight, and stated that the “Research Use Only” labeling did not change its reading of intended use. It classified retatrutide, tirzepatide, and the bacteriostatic water sold beside them as unapproved new drugs and asked for a written response within fifteen working days.

01 / WHAT FDA REVIEWED

One website, three products, a three-month window

The letter, dated March 31, 2026 and issued by the Center for Drug Evaluation and Research, opens by stating that FDA reviewed grampeptides.com from January to March 2026. It names three products offered for sale in the United States: “Retatrutide” (which the site also called “GLP-1-R peptide”), “Tirzepatide” (also called “GLP-2 peptide”), and “Bacteriostatic Water for Injection.”

The first paragraph already states the conclusion the rest of the letter supports: FDA’s position is that these are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, and that shipping them in interstate commerce is inconsistent with sections 301(d) and 505(a).

The second paragraph explains why FDA treats this category as a public-health priority. Injectable products bypass some of the body’s defenses against toxins and microorganisms, so the agency describes them as carrying a risk of serious harm.

02 / THE RUO PARAGRAPH

FDA quotes the disclaimer, then sets it aside

The third paragraph is the one most operators should read twice. FDA writes: “Despite statements on your product labeling marketing your products for ‘Research Use Only,’ and ‘not intended for human consumption, medical use, or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”

Two things are happening in that sentence. FDA acknowledges the boundary language exists, and it states that the rest of the site outweighs it. The agency then cites the definition of a drug in section 201(g)(1): a product intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or function of the body.

The letter does not argue the disclaimer was hidden or poorly worded. It treats the disclaimer as one statement on the site and the product descriptions as other statements on the same site, and reads them together.

03 / THE CLAIMS QUOTED

The product-page language FDA lifted

FDA introduces its examples with a phrase worth noting: the quoted statements “provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs,” and the list “may not be limited to” what follows. The agency is showing its evidence, not exhausting it.

From the retatrutide product page, FDA quoted three statements:

• “[I]nfluences appetite suppression, insulin sensitivity, thermogenesis, and fat-oxidation models.”
• “[D]emonstrated significant potential for reducing body weight, improving glucose handling, and enhancing lipid metabolism.”
• “GLP-1-R peptide acts through coordinated activation of: GLP-1 receptors – improving glucose response, slowing gastric emptying, and reducing appetite.”

04 / THE SECOND PRODUCT

A benefits list framed as research

From the tirzepatide page, FDA quoted a “Benefits of GLP-2 Peptide” list with three entries: metabolic regulation, described as “studied for its ability to lower glucose and support balanced insulin levels”; weight management, “associated with significant decreases in body weight in both animal and human studies”; and improved lipid profiles, where “research shows reductions in triglycerides and improved cholesterol ratios.”

Each entry is phrased as a report on studies rather than a promise to a buyer. FDA quoted them anyway. The pattern across the two product pages is that words like “studied,” “models,” and “research shows” did not change how the agency read a list headed “Benefits.”

05 / THE WATER

Selling the diluent beside the peptide

The letter devotes its own paragraph to “Bacteriostatic Water for Injection.” FDA states that the site offers it “for sale alongside peptide products, which are drugs intended for injection and require reconstitution,” and that “the sale of these products together demonstrates that you intend for your ‘Bacteriostatic Water for Injection’ to be used in combination for injection. Therefore, your ‘Bacteriostatic Water for Injection’ is a drug.”

The water carried no outcome claims of its own. Its position in the catalog, next to products that require reconstitution before injection, was the evidence. This is the clearest example in the letter of FDA reading the storefront as a whole rather than page by page.

06 / THE LEGAL CHAIN

Four steps from “drug” to “unapproved new drug”

The letter’s reasoning follows a fixed sequence that appears across the peptide letters. Understanding it explains why the outcome does not turn on the label.

• Section 201(g)(1), 21 U.S.C. 321(g)(1): a product is a drug if it is intended to treat disease or affect the structure or function of the body.
• 21 CFR 201.128: intended use is shown by the objective intent of the people responsible, as evidenced by labeling, advertising, written statements, and the circumstances of distribution. The product pages and the bundled water were treated as that evidence.
• Section 201(p), 21 U.S.C. 321(p): a drug is a “new drug” unless it is generally recognized as safe and effective for the uses suggested in its labeling. FDA stated these products are not.
• Sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d): a new drug needs an approved application before it enters interstate commerce, and FDA stated that none is in effect for these products.

07 / WHAT FDA ASKED FOR

Fifteen working days and a paper trail

The conclusion section states that the cited items are “not intended to be an all-inclusive statement of violations,” and that the firm is responsible for investigating causes and preventing recurrence. It warns that failure to address the matter “may lead to regulatory or legal action including, without limitation, seizure and injunction.”

FDA asked for a written reply within fifteen working days of receipt, describing the specific steps taken, explaining how each step prevents recurrence, and attaching related documentation. If the firm disagrees, FDA invites its reasoning and supporting information. If correction cannot be finished in fifteen days, the firm is to state the reason and a completion date.

The response goes by email to the Office of Unapproved Drugs and Labeling Compliance, with the firm name and the identifier “721806” in the subject line. The letter was signed by the director of that office and posted to FDA’s site on April 7, 2026.

08 / WHAT TO REVIEW ON YOUR OWN SITE

Read your storefront the way this letter reads it

The letter is useful as a checklist because every piece of evidence it cites is something an operator can find on their own site without a lawyer. Work through each surface and record what you find and what you change.

• Product descriptions that name an effect in a body: appetite, glucose, insulin, body weight, lipids, or any organ or system.
• “Benefits” headings and bullet lists, including ones that cite studies or say “research shows.”
• Alternate product names that map to a drug class, such as “GLP-1-R peptide” for retatrutide.
• Bacteriostatic water, syringes, needles, or reconstitution kits sold alongside or cross-sold from peptide listings.
• Where the research-use-only statement sits, and whether the pages around it say something different.

See what a RUO Clear scan covers

QUESTIONS

Related questions

SOURCES

Sources cited

Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.